Tonix Pharmaceuticals - TNXP Business Value

This price chart clearly demonstrates competitive pressure, forcing Tonix Pharmaceuticals (TNXP) to accelerate research to capture market niches. The current Enterprise Value stands at -84.40. Management is focused on developing therapies for neurological pathologies, flexibly allocating budgets across various testing phases. Meanwhile, investors should consider the risk of equity dilution due to the regular issuance of shares to support an extensive pipeline of developments.

TNXP: tonixpharma.com Total Company Value 11/23/2025 - 10/30/2026

Tonix Pharmaceuticals (TNXP) - metric breakdowns and financial figures

- share price and expert price forecast:

Share Price Tonix Pharma|TNXP - Consensus Target

- issuer market value details:

Market Capitalization Tonix Pharmaceuticals|TNXP - Total Company Value

- balance sheet net asset value indicators:

Share Book Value Tonix Pharmaceuticals|TNXP - Company Book Value|Market Capitalization to Net Assets tonixpharma.com|TNXP - Company Total Assets

- debt level and financial liquidity data:

- earnings and valuation multiples information:

TNXP - Net Income

Analysis of all company metrics:Tonix Pharma

From a portfolio management perspective, this indicator determines the actual acquisition cost of an asset by summing the market capitalization and net debt to eliminate the impact of temporary cash balances. By analyzing the valuation of Tonix Pharmaceuticals (TNXP) via the EV metric, an investor sees the real cost of ownership for the drug portfolio, where the value of legacy molecules is adjusted for the holding's debt load.

Competitors of Tonix Pharmaceuticals (TNXP)

HLN: Business Value|KVUE: Real Price to Acquire Entire Company|VRNA (Verona Pharma Inc.) - Business Value|Jyong Biotech Ltd (MENS) - Total Company Value|Full Business Value LGND (ligand.com)|Total Company Value Amneal|Perrigo Company PLC - Full Business Value|Enterprise Value ALVO|LQDA (Liquidia Inc.) - Value Adjusted for Debt and Cash|Enterprise Value GLPG (Galapagos NV)|Enterprise Value anipharmaceuticals.com ANIP|MNKD - Total Company Value|Value Adjusted for Debt and Cash AMPH (Amphastar Pharmaceuticals Inc)|Pacira (PCRX) - Total Company Value|Real Price to Acquire Entire Company ARS Corp|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com|Real Price to Acquire Entire Company SCPH (scPharmaceuticals Inc.)|TECX (tectonictx.com) - Value Adjusted for Debt and Cash|Total Company Value China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Total Enterprise Value|BHST: Real Price to Acquire Entire Company|invizyne.com - Aggregate Business Value|ORMP: Enterprise Value|Entera Bio - Value Adjusted for Debt and Cash|HYFT (MindWalk) - Enterprise Value|Total Enterprise Value ABVC BioPharma, Inc ABVC|Total Company Value Cumberland Pharmaceuticals (CPIX)|QNTM (quantumbiopharma.com) - Value Adjusted for Debt and Cash|FibroGen - Real Price to Acquire Entire Company|Aggregate Business Value TELO (Telomir Pharmaceuticals Inc)|RANI - Total Company Value|Total Enterprise Value Synergy CHC Corp|rallybio.com (RLYB) - Total Company Value|Business Value LEXX|PULM (Pulmatrix) - Enterprise Value|Pheton (PTHL) - Company Buyout Price|Real Price to Acquire Entire Company APM (Aptorum Group Limited)|Lyra Therapeutics Inc - Business Value|Impact BioMedical - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TNFA|YCBD - Total Company Value|Full Business Value PRFX|CYTO: Enterprise Value|Lipella Pharma - Value Adjusted for Debt and Cash|OPTN (OptiNose, Inc.) - Enterprise Value|Enterprise Value pieris.com|Total Company Value Procaps (PROC)|PTPI (Petros Pharmaceuticals Inc) - Value Adjusted for Debt and Cash|Total Company Value Qilian International Holding Group Limited QLI|SLRN - Real Price to Acquire Entire Company|TFF Pharmaceuticals - Enterprise Value